Blair William & Co. IL Sells 120,502 Shares of DexCom, Inc. $DXCM

Blair William & Co. IL lowered its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 5.7% during the fourth quarter, Holdings Channel reports. The firm owned 1,988,841 shares of the medical device company’s stock after selling 120,502 shares during the period. Blair William & Co. IL’s holdings in DexCom were worth $131,999,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. CVA Family Office LLC raised its holdings in DexCom by 48.5% during the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after buying an additional 147 shares in the last quarter. MCF Advisors LLC bought a new stake in shares of DexCom during the 4th quarter worth about $32,000. ORG Partners LLC increased its holdings in shares of DexCom by 124.3% during the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 281 shares during the last quarter. Spire Wealth Management increased its holdings in shares of DexCom by 113.8% during the 4th quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock valued at $38,000 after acquiring an additional 305 shares during the last quarter. Finally, Aventura Private Wealth LLC bought a new position in shares of DexCom in the 4th quarter valued at approximately $43,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Buying and Selling

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the company’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $59.91, for a total value of $101,847.00. Following the sale, the executive vice president directly owned 109,504 shares in the company, valued at $6,560,384.64. This represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of the stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $72.00, for a total value of $1,926,648.00. Following the transaction, the insider owned 382,482 shares of the company’s stock, valued at $27,538,704. This represents a 6.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 40,994 shares of company stock valued at $2,919,022 over the last ninety days. Company insiders own 0.28% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Benchmark assumed coverage on DexCom in a report on Monday, May 11th. They issued a “buy” rating and a $77.00 target price for the company. Sanford C. Bernstein set a $77.00 price target on shares of DexCom in a research report on Friday, May 1st. Canaccord Genuity Group set a $82.00 price objective on shares of DexCom and gave the stock a “buy” rating in a research note on Monday, May 18th. Citigroup reiterated a “buy” rating and issued a $84.00 price objective (up from $79.00) on shares of DexCom in a research note on Thursday, May 28th. Finally, Barclays reiterated an “underweight” rating and set a $64.00 price target (down from $67.00) on shares of DexCom in a report on Monday, May 18th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $84.83.

DexCom Stock Down 1.4%

DXCM opened at $73.16 on Wednesday. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $89.98. The company has a market capitalization of $28.23 billion, a P/E ratio of 31.26, a P/E/G ratio of 1.16 and a beta of 1.45. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. The firm’s fifty day moving average price is $66.59 and its two-hundred day moving average price is $67.76.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm’s revenue for the quarter was up 15.0% compared to the same quarter last year. During the same period last year, the firm earned $0.32 EPS. On average, analysts anticipate that DexCom, Inc. will post 2.58 EPS for the current year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.